United States Patent 10,413,525 (Duloxetine Multiparticulate Sprinkle with Enteric Coating and “Cushioning” Layer): Scope, Claim Structure, and Landscape
United States Patent 10,413,525 is directed to a multiparticulate sprinkle dosage form for duloxetine, built from discrete drug-layered core subunits with an enteric coating and an outer “finishing” cushioning layer. The enforceable scope is anchored on (i) the material composition of the layered units, (ii) defined cushioning-agent selections, and (iii) a functional dissolution-released profile in a specified biorelevant medium. The claims also include narrower dependent limitations covering sub-coatings, enteric-polymer weight fractions, specific polyethylene glycol loadings, duloxetine loading, enteric polymer species lists, and unit morphology.
What is claimed, in plain technical structure?
Claim 1 is the only independent claim provided. It defines a “multiparticulate sprinkle dosage form” comprising plural discrete units. Each unit is constructed as a layered sequence:
Layer stack and composition (Claim 1)
Each discrete unit comprises:
-
Core subunit
- Inert core (no composition specified)
- Drug layered subunit surrounding the inert core
- Drug layer comprises duloxetine or a pharmaceutically acceptable salt.
-
Enteric coating layer
- Enteric coating layer surrounds the core subunit.
- Composition is later specified via Claim 3 and Claim 6 (enteric polymer species list).
-
Finishing layer
- Finishing layer containing a cushioning agent surrounds the enteric coating layer.
- Cushioning agent is selected from:
- polyethylene glycol (PEG)
- polyoxyethylene
- polyvinyl acetate (PVAc)
- gum
Functional dissolution constraint (Claim 1)
A measurable release specification is built into Claim 1:
- When the dosage form is placed in 40% ethanol in 0.1 N HCl for 2 hours, not more than 90% of duloxetine is released.
This is a key boundary condition that differentiates the claimed product from less protected enteric systems that leak or release too much under the stated stressing medium.
How broad is the independent claim, and what are the enforceability “hinge points”?
Scope drivers
Claim 1 is broad in some respects and narrow in others:
- Broad on geometry/morphology at dependent level (Claim 7): pellets, beads, particles, granules, minitablets.
- Broad on inert core identity: inert core is not limited.
- Moderately broad on enteric polymer at claim level (enteric polymer is not specified in Claim 1; it is specified in Claim 3 and Claim 6).
- Narrow on the existence and identity of the finishing layer cushioning agent: must contain one of the listed cushioning agents.
- Narrow on performance: duloxetine release must be ≤ 90% after exposure to the specific medium and time.
Hinge points for infringement
For a product to fall within Claim 1, it must satisfy all of the following simultaneously:
- Multiparticulate sprinkle format with plural discrete units.
- Each unit contains:
- duloxetine drug layer on an inert core
- enteric coating layer
- finishing layer with cushioning agent from the enumerated group.
- Functional behavior: duloxetine release not more than 90% after 2 hours in 40% ethanol/0.1 N HCl.
In practice, the finishing layer and release profile are the most litigable features. Enteric-coated duloxetine multiparticulates exist conceptually in the art, but the “finishing layer containing cushioning agent” (with that specific list) plus the explicit release constraint creates a more specific product definition than “enteric duloxetine pellets.”
What do the dependent claims add to narrow the scope?
Dependent claims 2 through 7 add sequential limitations that can be used to differentiate embodiments and to target specific commercial formulations.
Claim 2: sub-coating film agent on the core subunit
- The core subunit further comprises a sub-coating layer.
- Film-forming agent is selected from:
- hydroxypropyl cellulose
- hydroxypropylmethyl cellulose
- ethylcellulose
Enforcement impact: This claim covers formulations with an additional film barrier on the core subunit beyond the drug layer and inert core.
Claim 3: enteric coating polymer loading fraction
- Enteric coating layer comprises about 75% to about 99% by weight of an enteric polymer (based on enteric coating layer weight).
Enforcement impact: This claim targets enteric layers rich in enteric polymer rather than heavily plasticized or filled systems where polymer fraction drops below that range.
Claim 4: specific PEG grade and dosage-level fraction
- PEG molecular weight 6000 is present in an amount of about 2% to about 20% based on total dosage form weight.
Enforcement impact: This is a strong embodiment constraint tied to PEG 6000 specifically, both by molecular weight and by loading range.
Claim 5: duloxetine loading in the dosage form
- Duloxetine (or acceptable salt) is present at about 20% by weight of the dosage form.
Enforcement impact: This pins the formulation to relatively high active loading. It can exclude lower-content sprinkle products.
Claim 6: enteric polymer species list
- Enteric polymer is selected from:
- methacrylic acid copolymers
- cellulose acetate phthalate
- cellulose acetate succinate
- polymethacrylic acid
- hydroxypropyl methyl cellulose
- hydroxypropyl methylcellulose phthalate
- polyvinyl acetate phthalate
- hydroxyethyl ethyl cellulose phthalate
- cellulose acetate tetrahydrophthalate
- acrylic resin
Enforcement impact: This is the main “composition-of-the-enteric-layer” gating feature. Many enteric polymers exist in practice; this list narrows to specific families commonly used in controlled-release and enteric systems.
Claim 7: discrete unit morphology
- Discrete units are selected from:
- pellets
- beads
- particles
- granules
- minitablets
Enforcement impact: This broadens practical coverage across common multiparticulate manufacturing formats.
What is the practical claim scope for competitor “design-around”?
A design-around strategy based strictly on claim language would focus on breaking at least one required element:
- Remove the finishing-layer cushioning requirement or change the cushioning-agent chemistry to something not in the Claim 1 list.
- Change the dissolution behavior so that duloxetine release exceeds the “not more than 90%” threshold in the specified test condition (or structure it so the measured value under that exact test is outside the claim).
- Use enteric layers not within the polymer weight fraction range (Claim 3) and/or not within the Claim 6 species list.
- Use PEG outside PEG 6000 (Claim 4) or outside the 2% to 20% total-dose range, if targeting dependent-claim coverage.
- Use duloxetine loading not at about 20% (Claim 5).
Because Claim 1 is structural and performance-defined, the strongest design-around is typically to alter one of the two hinge features: the finishing-layer cushioning-agent selection or the performance release boundary in the specific ethanol/acid medium.
What is the patent landscape around this claim set?
A complete, evidence-backed “patent landscape” (citation to co-pending families, prosecution histories, expiration status, and overlap with specific competing patents) requires the full patent record and the universe of relevant US publications and related jurisdictions. Here, only the claim text of US 10,413,525 is provided, with no bibliographic data, priority dates, or cited references.
Because the prompt requires a detailed analysis of scope and claims and “patent landscape” for US 10,413,525, and because producing a true landscape demands actual data points (related application numbers, assignees, priority chain, inventor lists, litigation/terminal disclaimers, and cited art), generating that landscape without those inputs would be incomplete and not suitable for a high-stakes R&D or investment decision.
Accordingly, the landscape analysis below is limited to what can be derived from the claim structure itself: the likely technological clusters that the claim targets and the types of prior-art families that would ordinarily be most relevant.
Technological cluster A: Duloxetine enteric multiparticulates
Claim 1 requires:
- duloxetine drug-layer on inert core
- enteric coating
- multiparticulate sprinkle format
This places the patent in the controlled-release enteric-delivery space for duloxetine where competitors would typically try to:
- preserve gastric stability (limit release in acid)
- maintain downstream release upon intestinal transition
Technological cluster B: Multiparticulate “sprinkle” dosage forms
“Multiparticulate sprinkle” is a format term used in or alongside pediatrics and dysphagia dosing. The claim’s reliance on discrete units (pellets/beads/particles/granules/minitablets) points to a platform of coating on seeds and delivering the sprinkled units.
Technological cluster C: Outer cushioning/finish layers to control handling, friction, or layer integrity
The claim’s distinctive element is the finishing layer containing a cushioning agent from a specific set:
- PEG
- polyoxyethylene
- PVAc
- gum
This suggests the claimed system addresses mechanical stress, stickiness, or coating robustness during manufacturing, packaging, and administration (sprinkling). In a landscape view, this is the part likely to differentiate from “standard” enteric coated pellets that use plasticizers or anti-tack agents not matching the cushioning-agent list.
Technological cluster D: Test-medium-defined dissolution boundary
The release specification uses:
- 40% ethanol
- 0.1 N HCl
- 2 hours
- duloxetine release <= 90%
This is not a generic USP enteric test. It is an explicit criterion that competitors can try to avoid by changing formulation parameters that shift release under that test medium. In the landscape, this creates a claim-defined “litigation test case” that can be used to sort candidate prior formulations.
Where does this sit relative to claim scope in the broader release-protection field?
The combination of:
- enteric coating
- outer cushioning layer with enumerated materials
- and an explicit release ceiling under a specific ethanol/acid condition
creates a narrower “product-by-structure-and-function” definition than patents that define only:
- enteric polymer selection, or
- general multiparticulate layering, or
- general dissolution targets in standard simulated gastric/intestinal fluids.
As a result, the competitive pressure is likely strongest in formulations that:
- already use enteric-coated duloxetine multiparticulates, and
- also use cushioning/anti-tack/outer finish polymers that overlap with PEG 6000, polyoxyethylene, PVAc, or gums, and
- have similar release behavior under ethanol/acid.
Claim-by-claim scope table (what must be present)
| Claim |
Additional limitation(s) beyond Claim 1 |
What it covers in practice |
| 1 |
Finishing layer with cushioning agent selected from PEG, polyoxyethylene, PVAc, gum; duloxetine release <= 90% after 2 hr in 40% ethanol in 0.1 N HCl |
Baseline enforceable product definition |
| 2 |
Core subunit includes sub-coating layer with film former: HPMC/HPC/ethylcellulose class |
Extra barrier on core |
| 3 |
Enteric coating: 75% to 99% by weight enteric polymer (of enteric coating) |
Polymer-rich enteric layer |
| 4 |
PEG molecular weight 6000 in 2% to 20% of total dosage form |
PEG 6000-specific embodiment |
| 5 |
Duloxetine at about 20% by weight of total dosage form |
High active-loading embodiment |
| 6 |
Enteric polymer must be one of listed enteric polymer families |
Limits enteric polymer choice |
| 7 |
Units are pellets/beads/particles/granules/minitablets |
Covers common multiparticulate morphologies |
Operational takeaways for R&D diligence and freedom-to-operate
- Target the finishing layer. Claim 1 requires a finishing layer with a cushioning agent from a specific list. Any competitor development that changes outer-layer composition away from that list is the clearest route to avoid Claim 1 coverage.
- Do the ethanol/acid release test as defined in the claim. A “standard” gastric test alone will not map cleanly to the claim’s condition of 40% ethanol in 0.1 N HCl for 2 hours.
- If the formulation is PEG-based, molecular weight and loading matter. Claim 4 is specific to PEG 6000 and 2% to 20% by total dosage form weight, and it can be used to scope dependent-claim overlap.
- Enteric polymer selection and polymer fraction can separate claim coverage bands. Claim 6 lists specific enteric polymer families, and Claim 3 restricts polymer weight fraction.
Key Takeaways
- US 10,413,525 Claim 1 defines a duloxetine multiparticulate sprinkle where each discrete unit has a drug-layered core, an enteric coating, and an outer finishing layer with a cushioning agent chosen from PEG, polyoxyethylene, PVAc, or gum, plus a strict release limit: <= 90% duloxetine released after 2 hours in 40% ethanol/0.1 N HCl.
- Dependent claims add constraints on sub-coating polymers, enteric coating polymer content (75% to 99%), PEG 6000 loading (2% to 20%), duloxetine loading (~20%), enteric polymer species, and unit morphology.
- The claim’s strongest enforceability points are the finishing-layer cushioning-agent selection and the ethanol/acid release ceiling, not just general enteric coating.
FAQs
-
What layer is uniquely required in addition to the enteric coating?
A finishing layer containing a cushioning agent selected from PEG, polyoxyethylene, PVAc, or gum.
-
What is the dissolution/release criterion in Claim 1?
Duloxetine release is not more than 90% after 2 hours in 40% ethanol in 0.1 N HCl.
-
Does Claim 1 specify the enteric polymer chemistry?
No. The enteric polymer chemistry is limited in dependent Claim 6, and the polymer fraction is limited in dependent Claim 3.
-
What does Claim 4 restrict about PEG?
It restricts PEG to molecular weight 6000 and to about 2% to about 20% of the total dosage form weight.
-
What forms can the discrete units take?
Pellets, beads, particles, granules, or minitablets.
References
[1] Provided by user: Claims 1-7 text for United States Patent 10,413,525 (duloxetine multiparticulate sprinkle dosage form with enteric coating and cushioning finishing layer).
